Publication: The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease
1
Issued Date
2013-07-01
Resource Type
ISSN
14220067
16616596
16616596
Other identifier(s)
2-s2.0-84880249861
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Molecular Sciences. Vol.14, No.7 (2013), 13909-13930
Suggested Citation
Kiyoshi Kikuchi, Salunya Tancharoen, Nobuyuki Takeshige, Munetake Yoshitomi, Motohiro Morioka, Yoshinaka Murai, Eiichiro Tanaka The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease. International Journal of Molecular Sciences. Vol.14, No.7 (2013), 13909-13930. doi:10.3390/ijms140713909 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/31284
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease
Other Contributor(s)
Abstract
Edaravone was originally developed as a potent free radical scavenger, and has been widely used to treat acute ischemic stroke in Japan since 2001. Free radicals play an important role in the pathogenesis of a variety of diseases, such as cardiovascular diseases and stroke. Therefore, free radicals may be targets for therapeutic intervention in these diseases. Edaravone shows protective effects on ischemic insults and inflammation in the heart, vessel, and brain in experimental studies. As well as scavenging free radicals, edaravone has anti-apoptotic, anti-necrotic, and anti-cytokine effects in cardiovascular diseases and stroke. Edaravone has preventive effects on myocardial injury following ischemia and reperfusion in patients with acute myocardial infarction. Edaravone may represent a new therapeutic intervention for endothelial dysfunction in the setting of atherosclerosis, heart failure, diabetes, or hypertension, because these diseases result from oxidative stress and/or cytokine-induced apoptosis. This review evaluates the potential of edaravone for treatment of cardiovascular disease, and covers clinical and experimental studies conducted between 1984 and 2013. We propose that edaravone, which scavenges free radicals, may offer a novel option for treatment of cardiovascular diseases. However, additional clinical studies are necessary to verify the efficacy of edaravone. © 2013 by the authors; licensee MDPI, Basel, Switzerland.